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Abstract  
 
This study compares lifetime prevalence and age of first use (onset) for alcohol, cannabis, and other 
drugs in six international sites. Data from seven epidemiologic field surveys that used compatible 
instruments and study designs were compiled for cross-site analyses by the International Consortium 
of Psychiatric Epidemiology (ICPE). The world health organization’s composite international 
diagnostic instrument (WHO-CIDI) and additional items were used to ascertain drug use in each site. 
Lifetime use rates were estimated for alcohol, cannabis, and other illicit drugs. Survival analyses were 
used to estimate age of onset. Study settings and main results: use of alcohol twelve or more times 
ranged in descending order from the Netherlands (86.3%), United States (71.7%), Ontario, Canada 
(71.6%); São Paulo, Brazil (66.1%), Munich, Germany (64.9%), Fresno, California (USA) (51.9%), to 
Mexico City (43.2%). Use of cannabis five or more times in a lifetime ranged from 28.8 in the United 
States to 1.7% in Mexico City, and other drugs ranged from United States (19.4%) to Mexico City 
(1.7%). Age of first use was similar across study sites. This study demonstrates the fundamental 
uniformity of onset patterns by age as contrasted with wide variations in lifetime prevalences across 
sites. Study findings suggest that drug use patterns may change among emigrating populations from 
low consumption nations as a consequence of international resettlement in nations with higher rates. 
Methodological limitations of the study along with recommendations for future international 
comparative research are discussed.    
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1. Introduction  
 
Substance abuse produces an enormous burden on many societies. For example, in the United 
States the impact of substance abuse on health care, criminal justice system, and related 
economic burdens, was estimated at $414 billion in 2001 (Hegan et al., 2001). It is important 
to understand how drug use patterns are changing throughout the world. Cross-national and 
regional studies provide a benchmark for evaluating trends and cyclical shifts in drug use. 
This information is useful for assessing the feasibility of public policies for control and 
prevention of substance abuse, and for estimating economic costs of drug and alcohol use in 
different societies. These studies can be used to address basic substance abuse research issues 
such as the economic, social, and cultural determinants of prevalence, intensity, progression, 
and co-morbidity (Kessler et al., 1999; Merikangas et al., 1998). This article presents 
information about lifetime prevalence rates and age of onset for alcohol, cannabis, and other 
drug use reported from several nations and regional sites in North America and Europe. 
Results from these studies have been aggregated through the auspices of the international 
consortium of psychiatric epidemiology (ICPE).  
 
In the absence of readily available national survey data, the United Nations has often relied on 
reports of treatment seeking, convenience samples, and narcotics trafficking to estimate the 
intensity of international drug use (Adrian, 1996). However, these approaches are misleading 
for making population estimates of lifetime drug use. A persistent limitation of using surveys 
conducted in North America and Europe for making epidemiologic comparisons is the non-
comparability of designs and protocols. This problem has impeded the compilation of 
databases from various countries suitable for cross-site analyses of rates and patterns of use 
(Jutkowitz and Eu, 1994; Hughes et al., 1983; Smart and Murray, 1985). Comparability is the 
standard of a truly international epidemiology of drug use, and until now this has only been 
possible in alcohol studies.  
 
Most national surveys reported in the public health and substance abuse literature are about 
adolescent drug use. These studies have estimated rates of drug use using school-based 
samples (Vega et al., 1998; Adlaf et al., 1997; Johnston et al., 1997; Smart et al., 1988; 
DeZwart et al., 1997; Caravalho et al., 1995; Medina- Mora et al., 1993; Scholz and 
Kaltenbach, 1995; Uchtenhagen, 1984; Driessen et al., 1989; Korf, 1988). Important 
exceptions are the surveillance data about adults collected regularly by survey in the United 
States (National Institute on Drug Abuse, 1998) and Canada (Xie et al., 1998). Also, two 
national surveys conducted in the United States within the past decade provided extensive 
information about drug use prevalence and correlates, the National Comorbidity Survey 
(NCS; Kessler, 1995) and the National Longitudinal Alcohol Epidemiologic Survey (Grant, 
1996, 1997). Other examples of multiple national and metropolitan adult drug use surveys are 
found in Mexico (Galvan-Reyes et al., 1997; Tapia-Conyer et al., 1996) and the City of 
Amsterdam in the Netherlands, which also is the site for periodic adult surveys (Sandwijk et 
al., 1991). Collectively, these surveys have estimated adult substance use, primarily for 
alcohol.  
 
National studies that have compared alcohol use and rates for other drugs routinely report that 
alcohol is the most widely used substance (Perkonigg et al., 1998; Holly and Wittchen, 1998; 
Senay, 1991). Cross-national rates for lifetime alcohol use are similar in the United States, 
Canada, and in Europe. Variations in alcohol use rates in these societies are primarily a 
function of gender and cultural norms and legal controls governing use, including differences 
in the age of legal alcohol use. Consistently, women have lower lifetime rates than men. The 
sex differential is greatest in Latin American countries, such as Mexico, where cultural 
practices both constrain and sanction use of alcohol by women (Caetano and Carlini-Cotrim, 
1993; Caraveo-Anduaga et al., 1999). Much greater variation is found in epidemiologic 
estimates of cannabis use. The United States, Canada, Australia, and New Zealand report 
higher rates, in the range of 30/50% lifetime use (National Drug Strategy, 1996; Black and 
Casswell, 1993). European and Latin American nations are in a range from 5 to 15% 
(MacCoun and Reuter, 1997). Total international lifetime use of cannabis is estimated at 141 
million users (United Nations International Drug Control Programme, 1997). Regrettably, 
adequate data for estimating cocaine and other drug use are less available or reliable, but what 
has been reported mirrors cross-national variations in rates of cannabis use. The United States 
and Canada have far higher prevalence levels than other nations in recent decades since 
WWII (Erickson et al., 1987).  
 
2. Methods  
 
2.1. Samples  
 
Seven surveys carried out in six countries are included in these analyses. Descriptive 
information about the seven surveys and locations is presented in Table 1 with appropriate 
references. These references provide details on the study designs. The surveys were carried 
out in North America, Latin America, and Europe, with a total sample size of 27 255. All 
surveys were based on general population probability samples rather than on patient samples 
or quota samples of the general population. All interviews were carried out face-to-face rather 
than on the telephone or through mail questionnaires. The age ranges for the respective 
samples are shown in Table 1, and the age range for the analyses presented below was limited 
to 14-54 year olds across sites. Response rates in the separate surveys were between 60.4 and 
90.0%. This study compares regional and national samples. These samples include one 
regional study from Central (Fresno) California to contrast patterns of drug use prevalence 
and onset among Mexican Americans with samples from Mexico City and the USA. This 
offers an opportunity to examine what happens to rates of drug use consumption when 
individuals migrate from one nation to another.  
 
2.2. Substance use variables  
 
The lifetime estimates presented in this paper include drugs not available through medical 
sources, including physicians, and substances that are legitimate pharmaceutical products but 
were consumed without prescription or at amounts other than those prescribed by a medical 
professional. The drug groups include, (1) alcohol; (2) cannabis including marijuana and 
hashish; (3) opioids including heroin, morphine and other analgesics such as codeine; (4) 
stimulants other than cocaine such as methamphetamine; (5) anxiolytics such as sedatives and 
tranquilizers; (6) psychedelics such as LSD, peyote; and mescaline; (7) cocaine; and (8) 
inhalants such as gasoline or spray paint. Lifetime estimates for the use of these substances is 
based on reported use of alcohol at least 12 times and other substances on at least five 
occasions. Comparisons of prevalence rates for Germany were limited in scope because the 
sample was restricted to the age range 14-24.  
 
2.3. Data analysis  
 
Analyses presented in the tables and figures of this paper incorporate the design features of 
the probability samples for each survey data set including stratification and clustering of 
sample individuals and weighting of responses. All estimates are weighted by case-specific 
analysis weights designed to compensate for varying selection probabilities, differential non-
response rates and available post-stratification adjustments (Heeringa et al., 1997). Although 
other procedures are available, compensation was used for differential selection probabilities 
and response rates in making estimations. Post-stratification weighting of sample estimates 
was used to reduce potential bias due to sample non-coverage of the target populations (Little, 
1991). Standard errors of prevalence estimates reported in the tables of this paper were 
computed using special software for Jackknife repeated replications (JRR) variance 
estimation and reflect the effects of the surveys’ complex sample designs and post-
stratification adjustments (Wolter, 1965).  
 
Prevalence estimates of lifetime substance abuse reported from surveys other than the ICPE 
surveys were not re-estimated from original data but are presented as given in other published 
sources (Table 1). ICPE survey estimates of lifetime prevalence of substance abuse for total 
populations (Table 2) and genders (Table 3) are weighted estimates computed using the 
combined ratio estimator of population proportions, r=Σi WiYi / Σi Wi , where Yi=1 if case i 
meets lifetime criteria, 0 otherwise, and Wi is the analysis weight for the i-th sample case 
(Kish, 1965).  
 
Age of onset analyses are reported as weighted estimates of age-specific hazard rates for first 
use of a substance (Kalbfleisch and Prentice, 1980). The analyses are based on survey data 
from four of the seven sites: NCS, Fresno, Mexico City and Ontario. All estimates of age-
specific hazards rates were computed using the SAS® PROC LIFETEST procedure. Hazard 
rate estimates were computed by the life table method. The estimated agespecific hazard rates 
are evaluated at the midpoint of each yearly age interval and were not adjusted in this analysis 
for other covariates such as gender or birth-year cohort. Weighted survey estimates of the age-
specific hazard rates were achieved by substituting weighted frequencies in the estimation of 
age-specific ‘failurerates,’ where a ‘failure’ is interpreted as the experience of first use of a 
substance. Thus, the hazard rate for first use of a substance at age t is estimated as:  
 
ĥ(t) = ˆq(t) / (1 - ˆq(t) / 2)  
 
where, ˆq (t)=d(t)/n(t) is the ‘failure rate’ at time t ; d(t) is the weighted count of first uses of a 
substance at time t ; n(t) is the weighted count of persons ‘at risk’ at time t .  
 
3. Results  
 
Estimates (with standard errors) of the lifetime prevalence of substance use for individual 
drugs are presented in Table 2. Although alcohol and cannabis are the most widely consumed 
substances across all sites, prevalence rates of other drugs are extremely varied. For example, 
inhalant use is highest in the United States and São Paulo, Brazil, compared with all other 
national sites. Cannabis and cocaine use is minimal in Mexico City. Alcohol use is 
significantly higher in the Netherlands (86.3%) than in any other site. Overall drug use rates 
are highest in the United States, Ontario and São Paulo, Brazil, ranging from 32.5 to 24.7%. 
In sites other than Fresno, California, total lifetime prevalence ranges from 16.6% in 14-24-
year olds in Munich, Germany, to a low of 2.9% in Mexico City.  
 
The lifetime rates in Fresno, Central California, are of special interest in these comparisons 
because this sample consists of Mexican-origin respondents, divided between immigrants 
(60.3%) and those born in the US (39.7%). They represent a population whose cultural 
antecedents are in Mexico, the country with the lowest rates of drug use, yet they are residing 
in the United States, a country with very high rates. The Fresno rates are lower than the 
national US rates derived from the NCS. Nevertheless, the Fresno rate (24.6%) is equivalent 
to Ontario (25.9%), and São Paulo (24.7%). These comparisons illustrate the increase in illicit 
drug use rates of re-socialization into American society primarily by first and second-
generation immigrants originating from a nation with a low prevalence of drug use.  
 
Table 3 presents lifetime substance use rates by gender, with standard errors. Cannabis is the 
second most likely drug to be used by both genders. Men have higher prevalence levels for 
alcohol, cannabis, and other drugs in all cross-national sites, but there are very wide variations 
across sites in rates for both genders. For example, lifetime use of cannabis among males 
ranges from 33.1 (NCS, USA) to 3.0% (Mexico City), and for women from 24.4 (NCS, USA) 
to 0.6% (Mexico City). Rates in Munich, Germany, and the Netherlands for cannabis are 
intermediate for both genders.  
 
In the Fresno sample, all gender comparisons are statistically significant. The rates for any 
drug use excluding cannabis among Fresno males is about the same as the NCS, USA rate for 
males, but the female rates are much higher in the NCS, USA, 17.1 and 10.8%, respectively. 
In comparison, gender differences in Mexico are not significant in five instances because the 
overall prevalence levels are negligible, except for alcohol. Other instances of minimal gender 
differences tend to occur in countries where overall use of particular drugs is low, such as 
inhalant use in Ontario, Canada, the Netherlands, and Munich, Germany, or opioid use in the 
Netherlands and São Paulo, Brazil, and psychedelics in São Paulo, Brazil, and in Munich, 
Germany.  
 
Women have major variations in rates of lifetime alcohol use across sites. Men and women of 
the Netherlands have the highest rates reported in this study, and women’s rates in that nation 
are higher than those reported by men in three sites, Mexico City, Munich, Germany, and 
Fresno, California. The female rate in the Netherlands for alcohol is four times higher than 
reported by women in Mexico City.  
 
Figs. 1-3 display age of onset (first use) information from the NCS, USA, Fresno, California, 
Mexico City, and Ontario, Canada surveys. Life table models were used to estimate age-
specific hazard rates for first use of alcohol, cannabis, and other drug use, in a lifetime. These 
hazard rates can be interpreted as the rates that persons of a specific age (who have not yet 
experienced first use) experience first use. Fig. 1 illustrates that alcohol use onset increases at 
age 11, and the curve accelerates in mid-adolescence to a peak age of 18. This is followed by 
a rapid decrease in new onsets during early adult hood (the early twenties) and a gradual 
tapering off thereafter. These patterns are fairly uniform.  
 
Fig. 2 presents cannabis use onset information. Cannabis has a short but intense onset period 
with rapid acceleration of first use between mid and late adolescence, then a rapid decrease 
after age 18 in the NCS, USA, 17 in Fresno, and 16 in Ontario, Canada. Although the rates are 
much lower, the age of onset pattern in Mexico City is similar to other samples in this study.  
 
Fig. 3 shows that drugs other than alcohol and cannabis have a longer onset curve, with lower 
onset rates during adolescence, but new onsets extending into middle adulthood. Peak age of 
first use in all sites occurs at age 18.  
 
4. Discussion  
 
We find great variation in rates of drug and alcohol use across the international samples 
reported in this study. Historically, higher population prevalence for illicit drug use has been 
reported in the United States than in other Western nations. Despite the ebb and flow of drug 
epidemics, rates remain very high. Ontario, Canada, appears to lag the US rates but may be 
reaching parity for some drugs. Mexico City, by comparison, has very low rates. Today, the 
Netherlands stands out prominently as having the highest alcohol rates among international 
sites in this study. These facts require scrutiny by public health policy and substance abuse 
experts in order to interpret their implications for future trends in all forms of drug use within 
and among nations. Given the findings we report, interpretations must be cautious and 
tentative. For example, very high rates of alcohol use in the Netherlands do not appear to have 
a strong influence on drug use rates, yet in the US a strong case could be made for this 
linkage. This finding alone opens the door to complex interpretations of public policy 
implications at both the individual (e.g. biogenetic vs. normative structures) and society levels 
(e.g. marketing vs. social control).  
 
Several decades of information about per capita alcohol use indicates substantial increases in 
consumption after WWII (Smart, 1989; Soyka, 1998). Consumption may have peaked in the 
United States, even as it increases in Latin America (US Department of Health and Human 
Services, 1997; Williams et al., 1994). Higher consumption levels may partially reflect a 
lower mean age of onset for drinking. US rates of illicit drug use appear to have increased 
from WWII until the 1980s, then reduced significantly thereafter (Grant, 1997; Anthony and 
Helzer, 1991; Abelson and Miller, 1985; Burke et al., 1991; Johnston et al., 1997; SAMHSA, 
1996). However, surveys conducted in the late 1980s and 1990s showed renewed increases of 
illicit drug use in different regions of North America, and a corresponding increase in Europe 
and Latin American, albeit, at much lower levels compared with the United States (Hughes et 
al., 1983; Adlaf et al., 1997; Senay, 1991; MacCoun and Reuter, 1997; Smart, 1989; Wittchen 
et al., 1998a,b,c). This period of time in the United States coincided with the infamous ‘crack’ 
cocaine epidemic in the United States, the advent of designer drugs such as ‘ecstasy,’ 
increasing methamphetamine and marijuana use, and most recently a resurgence of heroin 
use. This is also the time period when children of peak consumption ‘Baby Boomers’ entered 
their teenage years, and these youth may have disproportionately experienced an inter-
generational transmission of attitudes favorable to drug use. Nevertheless, overall rates of 
drug use in the United States have not returned to peak lifetime rates reported in the 1970s. In 
developed Western nations, as well as Australia and New Zealand, the few key studies that 
have been reported suggest drug use is reaching unprecedented levels of consumption despite 
remaining far below North American levels (Sylbing and Persoon, 1985; Muza et al., 1997; 
Carlini-Cotrim and Carlini, 1988). In less developed countries with traditional cultures, such 
as Nigeria, Egypt, Morocco, and India, rates remain far lower (Jutkowitz and Eu, 1994; Obot, 
1990; World Health Organization, 1997).  
 
Age of first drug use is an important risk factor for later dependence and experimentation with 
other drugs (Choquet et al., 1989; Escobedo et al., 1993; Hawkins et al., 1997; Kandel et al., 
1992). However, early initiation of alcohol use as a predictor of progression to dependence 
and illicit drug use is not firmly established in international studies. Grant and Dawson (1997) 
reported a US rate of 40% lifetime alcohol dependence for those who started drinking at 14 
years of age or younger, compared with only 10% for those who started at the age of 20 or 
older. Recent research has shown that younger age cohorts in the United States have used 
more drugs in their lifetime (SAMHSA, 1996). Early drug use is linked to negative 
consequences for social role functioning and impaired ability to make normative transitions 
from adolescence into adulthood (Newcomb and Bentler, 1988). The likelihood of higher 
educational attainment, forming successful marital unions, prospering in occupational 
pursuits, and avoiding mental disorders, is reduced by early initiation into drug use (Jutkowitz 
and Eu, 1994; Hawkins et al., 1992; Robins and Pryzbeck, 1985; Yu and Williford, 1992). It 
is an important public health goal to identify age of onset among nations and to determine the 
long-range consequences of these patterns. These are potentially harbingers of lost economic 
productivity, a host of secondary behavioral adjustment problems, and cost impact on the 
health care delivery system.  
 
Historical evidence suggests that it is problematic to forecast drug epidemics and changing 
popularity cycles of different drugs. There are mediating factors, such as variations in 
normative behavioral expectations that undermine simplistic forecasting of future trends. The 
rise and decline in the crack epidemic in the United States, and its selective regional and 
ethnic-racial penetration into the population, was completely unforeseen and continues to lack 
a credible, empirically founded explanation. Identification of national risk factors, rather than 
individual or group risk factors, responsible for fluctuations in drug use patterns is premature 
at our current state of knowledge. Similarly, the preference or avoidance of nations or their 
constituent ethnic and demographic groups for specific drugs, such as heroin or 
methamphetamine, requires much greater scrutiny to arrive at a satisfactory explanation.  
 
The study findings indicate that cultural assimilation into societies with high rates of drug use 
such as the United States or Canada may tend to accelerate the lifetime rates of drug use for 
newer immigrant groups from less developed nations toward the normative rates of these 
nations. Fresno, California, and its large Mexican origin population, provides an illustration of 
the consequences of moving from a low drug use to a high drug use society, and the 
extraordinarily degenerative impact on norms proscribing illicit drug use attributable to 
assimilation (Vega et al., 1998a). Detailed analyses of the Fresno data presented elsewhere 
have shown that nativity, acculturation level, gender, and location of residence independently 
contribute to lifetime illicit drug use in this population (Vega et al., 1998b). The influence of 
cultural and social assimilation appears to be progressive, and occurs within and across age 
cohorts with maximum effects on immigrants arriving as children (Turner and Gil, 2002). 
‘Long stay’ adult immigrants have higher lifetime rates of all types of drug use compared with 
‘short stay’ immigrants, and the second generation has even higher rates of drug dependence 
than ‘long stay’ immigrants (Vega et al., 1998a). Care must be taken to avoid premature 
closure in inferring causation. It is possible that reporting artifacts are having an unknown 
degree of influence on these self-reported rates. There may be a degree of underreporting in 
nations such as Mexico where fear of social stigma or punitive action resulting from personal 
disclosures of illicit drug use is prevalent. However, as discussed below in the limitations 
section, the magnitude of possible underreporting is unlikely to be great enough to distort the 
general patterns among sites reported in this study.  
 
This example highlights an understudied area for international research, the regulation of drug 
use by social sanctions and cultural norms, and their modification subsequent to assimilation 
in another society. Rates are lower in Mexico City even though there is extensive illicit drug 
production and trafficking in Mexico. Future national surveys in Mexico will afford an 
opportunity to observe whether the current marginal levels of drug use accelerate as a 
consequence of continuing trafficking activity and return migration from the US, and which 
regions are most affected by these influences. These findings will have implications for other 
nations experiencing large increases in illicit drug use supply and immigration, such as the 
Caribbean Basin and the Andes region of South America.  
 
Age-of-onset information reported in this study suggests a normative temporal ordering of 
peak onset from alcohol to cannabis to other drugs as a dominant pattern across study sites. 
This interpretation does not imply a progression sequence at the individual level since we 
have presented cross sectional data (Kandel et al., 1992). Perhaps somewhat counter-
intuitively, we detected no relationship between age of onset and prevalence levels for various 
substances in these regional and national samples. Age-of-onset patterns were fundamentally 
similar across sites regardless of wide variations in prevalence estimates and differences in 
legal age of drinking, suggesting a strong link to stages of adolescent development and the 
influence of social role transitions in early adulthood.  
 
4.1. Methodological limitations of the research  
 
Optimal and feasible strategies for pooling international data sets in the epidemiology of drug 
use are an important area of technical development. Even data sets sharing common data 
elements and design characteristics often have incompatibilities as well. The ICPE has 
selected various methodological techniques for different studies, including this one, and in 
some instances statistical artifacts may be produced by their use. It is important to 
acknowledge these possibilities in the context of improving the planning, execution, analyses, 
and interpretation of future multi-site international studies.  
 
Variations in response rates could reflect an unknown degree of selection bias, and other 
methodological differences, such as synthetic cohort assumptions required for survival 
analysis, cannot be entirely dismissed as a potential source of error in the hazard rate 
estimations for age of onset reported in Figs. 1-3. Since the surveys are cross-sectional, the 
age-specific rates involve comparisons among persons from different birth cohorts (i.e. a 
synthetic cohort). Longitudinal studies or much larger cross-sectional samples would be 
necessary in order to produce reliable age-specific estimates by birth cohort. It is possible that 
different birth cohorts could exhibit different age peaks in the hazard rates; were this the case, 
it would have the effect of broadening the peaks in the synthetic cohort. However, the peaks 
observed in Figs. 1-3 are remarkably sharp, with the exception of the Mexico City rates for 
cannabis and other drugs, which do not show clear peaks. Given the low prevalence of drug 
use in Mexico City, the hazard rates are predictably small; and, hence, have less precision 
than the estimates from other sites with much higher levels of drug use. The mixture of birth 
cohorts could also affect the level estimated for the hazard rates. For example, some birth 
cohorts (such as older ones) might be more resistant to drug use, and their exclusion from the 
analysis would likely raise the levels of the estimated hazard rates. Hence, the estimated 
hazard rates are of more interest for their relative changes and peaks than their numerical 
values. Again, however, the cross-sectional nature of the surveys and their limited sample 
sizes do not permit precise estimation of rates by birth cohort.  
 
It should be noted that the lifetime prevalence rates shown in Tables 2 and 3 reflect the nature 
and structure of the different study populations, including their differing age distributions. 
The site age distributions differ due to two factors: first, there are population differences, and, 
second, the samples had restricted age ranges that were not uniform. The Munich, Germany 
survey included only 14-25 year olds, thus limiting the comparability of this site to the other 
studies. All samples were constrained to respondents between 14 and 54 years, however, most 
of the samples did not have respondents under 18 years of age with the upper cut off being 54. 
There are alternative ways to present the prevalence data in Tables 1 and 2 that were not 
pursued here due to space limitations. One would be to standardize the age and gender 
distributions to some reference population. Although useful for comparison purposes, 
standardized rates are hypothetical constructs, and the non-standardized rates shown in Tables 
1 and 2 reflect the actual level of substance use in the site populations. We invite interested 
readers to review an additional analyses on the journal web site that suggest age distributions 
of the samples are not affecting the prevalence rates presented in Tables 2 and 3.  
 
The use of a diagnostic case-finding protocol, the CIDI, as the core instrument common to all 
survey sites, made it feasible to conform the standard of lifetime drug use in this study to 
respondent use on at least five occasions, and to at least 12 occasions for alcohol, in any 1 
year. We consider these operational criteria to represent a reasonable behavioral standard for 
estimating lifetime rates of drug use. Alternative standards, such as first use in a lifetime, or 
substance abuse or dependence diagnostic criteria, are other commonly used standards for 
estimating lifetime rates. Our intent was to identify prevalence and onset of persistence 
substance use, thus signaling self reinforcing behavior. Using these alternative standards 
could produce different results than reported here, especially if use in some nations or genders 
occurs disproportionately at frequencies below the threshold used in this study. However, the 
hazard curves presented in Figs. 1-3 are estimated based on the self-report of first use in a 
lifetime. Only four sites (US, Fresno, USA, Ontario, Canada, and Mexico) were included in 
these figures because the others did not collect information on first use in a lifetime. This 
underscores the importance of careful planning in advance of data collection to assure 
uniformity of data elements, not just core protocols such as the CIDI that are based on 
diagnostic criteria structure.  
 
There are also other issues not addressed in this study that may provide important additional 
information. Heterogeneous populations pose a variety of challenges for inclusion of 
subgroups least likely to be included in household samples, such as institutionalized 
populations, drug addicts, migrants, and the homeless.  
 
It is our opinion that artifacts, such as weighting prevalence estimates by site, veracity of self 
report data, and recall fallibility, do not fundamentally alter the patterns in reported rates. 
There is indirect evidence of reliability and validity from other studies. We have previously 
presented a comparison of DSM-III-R substance abuse or dependence rates in Fresno, 
California, using local county and US national (NCS) post stratification weighting for age and 
sex and found relatively minor differences (Vega et al., 1998). All major population surveys 
conducted in Mexico over many years have reported similarly low rates of illicit drug use, 
with negligible use among women, and previous research showed no differences in self-report 
veracity between Spain, Mexico, and the United States. A very large representative sample 
(N/28 000) of pregnant women in California was surveyed using anonymous urine 
toxicology screening in hospitals and negligible illicit drug use was found among Mexican 
immigrants (Vega et al., 1997). Rates for Mexican/American women were higher, with 
proportional differences similar in magnitude to those observed in the Fresno survey (Vega et 
al., 1998).  
 
4.2. Future directions  
 
International comparative studies have the unique value of permitting direct contrasts of 
levels of use by drug type and patterns of onset. Comparative studies also illustrate both 
methodological possibilities and challenges. These data taken from seven ICPE sites report 
wide variations across nations that provoke important research and policy questions. Can we 
anticipate a gender convergence in onset rates in developed nations and a corresponding 
convergence in abuse or dependence rates as younger age cohorts mature (Neve et al., 1996)? 
Will length of time between first use of individual drugs and onset of dependence vary in 
national samples? What is the relative vulnerability of urban and rural areas to drug use in 
different nations? How consistently across nations are immigrants and their offspring 
vulnerable to increased consumption patterns of drugs use after resettlement in high 
consumption nations? The future inclusion of comparable data from the WHO World Mental 
Health 2000 surveys in two dozen nations will provide an unprecedented opportunity to 
address many aspects of international substance use epidemiology and its economic impact on 
these societies, and will afford a unique possibility of planning and evaluating prevention and 
treatment programs in an international context (Fillmore et al., 1993).  
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